Sign in for the best experience.
Central airway obstruction (CAO) management depends on provider training and available local resources, making the clinical approach and outcomes highly variable. This guideline provides recommendations for management of symptomatic malignant and nonmalignant CAO.
ACCESS THE FULL GUIDELINE
For patients with symptomatic malignant or nonmalignant CAO, we suggest therapeutic bronchoscopy as an adjunct to systemic medical therapy and/or local radiation.
For patients with symptomatic malignant or nonmalignant CAO, we suggest the use of rigid bronchoscopy over flexible bronchoscopy for therapeutic interventions.
For patients with symptomatic malignant or nonmalignant CAO, we suggest the use of general anesthesia/deep sedation over moderate sedation for therapeutic bronchoscopy.
Advertisement
Our guidelines are aimed at helping you respond to today’s clinical challenges and improve patient health outcomes. Our panel of experts has developed multimedia content to facilitate adoption of this guideline into your day-to-day practice.
Malignant Central Airway Obstruction
This downloadable flowchart outlines the suggested treatment for patients presenting with a malignant CAO.
Nonmalignant Central Airway Obstruction
This downloadable flowchart outlines the suggested treatment for patients presenting with a nonmalignant CAO.
Guideline on Management of Central Airway Obstruction Released by CHEST In a release issued to the media, lead author, Kamran Mahmood, MD, MPH, FCCP, speaks to the importance of this guideline in practice.
CHEST offers education, networking opportunities, and articles on interventional pulmonary topics.
This Network advances multidisciplinary care and clinical practice in the areas of interventional procedures, pleural disease, and more.
Review our thoracic oncology resources in one place. See must-reads from the journal CHEST®, visual abstracts, and more.
Sign up for expert-led, hands-on simulation courses offering training in diagnostic bronchoscopy, pleural procedures, and more.